A Post-Authorization, Multicenter, Longitudinal, Observational Safety Registry Study for Patients Treated With Voretigene Neparvovec
Phase of Trial: Phase IV
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Voretigene neparvovec (Primary)
- Indications Leber congenital amaurosis
- Focus Adverse reactions
- Sponsors Spark Therapeutics
- 13 Dec 2018 Status changed from not yet recruiting to recruiting.
- 04 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Oct 2018.
- 12 Jul 2018 Status changed from planning to not yet recruiting.